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Continental Differences in Clinical
Characteristics, Management, and Outcomes
in Patients Hospitalized With Worsening Heart Failure
Results From the EVEREST (Efficacy of Vasopressin
Antagonism in Heart Failure: Outcome Study with Tolvaptan) Program
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Objectives Our aim was to examine continental and regional differences in baseline characteristics and post-discharge
clinical outcomes in the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with
Tolvaptan) trial.
Background Continental and regional differences in clinical trials of acute heart failure syndromes (AHFS) have not been well studied.
Methods We analyzed data from the EVEREST trial, which randomized 4,133 patients hospitalized for worsening (HF) and left
ventricular ejection fraction40% to oral tolvaptan, a vasopressin antagonist, or placebo and followed for a median
of 9.9 months. Baseline characteristics, mortality, and outcomes were analyzed across North America (n 1,251),
South America (n  688), Western Europe (564 patients), and Eastern Europe (n 1,619).
Results There were major differences between the 4 groups in the severity, etiology, and management of HF. Unadjusted
1-year mortality and cardiovascular mortality/HF hospitalization were 30.4% and 52.5% in North America, 27.2% and
41.6% in South America, 27.1% and 47.3% in Western Europe, and 20.5% and 35.3% in Eastern Europe. After ad-
justment, South American patients had the highest overall mortality (hazard ratio: 1.42, 95% confidence interval:
1.15 to 1.76), while Eastern European patients had the lowest cardiovascular death and HF hospitalization rate (haz-
ard ratio: 0.84, 95% confidence interval: 0.73 to 0.97), compared with patients in North America.
Conclusions Major continental and regional differences in HF severity, etiology, and management exist among AHFS patients,
resulting in varied post-discharge outcomes, despite pre-defined selection criteria. These differences should be
taken into account when planning global trials in AHFS. (Efficacy of Vasopressin Antagonism in Heart Failure:
Outcome Study with Tolvaptan [EVEREST]; NCT00071331) (J Am Coll Cardiol 2008;52:1640–8) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.056t
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teart failure (HF) is a major public health problem inter-
ationally. In the U.S. alone, 5 million individuals are
ffected, with 550,000 new cases yearly, 1 million hospi-
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November 11, 2008:1640–8 Continental Differences in Acute HFhe incidence of HF is rising in developing countries (3).
espite advances in medical therapy for chronic HF, the
umber of admissions for acute heart failure syndromes
AHFS) continues to rise, and mortality for these patients
emains high. Hospitalization for AHFS is one of the most
mportant predictors of morbidity and mortality in the
hronic HF population (4,5). In-hospital mortality rates are
% to 7% while 60- to 90-day mortality and readmission
ates are 7% to 9% and 24% to 30%, respectively (6).
See page 1649
As AHFS patients constitute a heterogeneous group,
ariations in patient characteristics may play a role in the
linical outcome of these patients. Contemporary registries
emonstrate important differences between continents and
egions within continents in HF etiology, HF severity, and
anagement of HF (7–13). As a result, cardiovascular (CV)
utcomes vary between these continents. However, in a
andomized trial, due to pre-specified inclusion and exclu-
ion criteria, it is expected that these differences are less
ikely to occur and may not influence the overall outcome of
trial. The EVEREST (Efficacy of Vasopressin Antago-
ism in Heart Failure: Outcome Study with Tolvaptan)
rogram demonstrated that the oral vasopressin antagonist,
olvaptan, added to standard therapy, improved some, but
ot all, HF signs and symptoms during hospitalization over
lacebo; it showed no effect on long-term mortality or
F-related morbidity (14,15). This large trial, which en-
olled patients from 3 continents and 2 regions in Europe,
rovides a unique opportunity to look at these continental
nd regional differences.
ethods
atients. The design of the EVEREST program has been
escribed previously (16). This prospective, international,
andomized, double-blind, placebo-controlled program ex-
mined the short- and long-term efficacy and safety of
olvaptan added to optimal medical therapy in patients
ospitalized for worsening HF. There were 2 identical
hort-term trials during the inpatient period (trials A and
), embedded in a long-term post-discharge outcome study
ombining all patients.
Adults 18 years of age with left ventricular ejection
raction 40%, hospitalized primarily for worsening of HF
nd with 2 or more signs of fluid overload, were randomized
ithin 48 h of hospitalization to oral tolvaptan (30 mg/day)
r matching placebo in addition to conventional therapy.
xclusion criteria were cardiac surgery within 60 days of
nrollment, cardiac mechanical support, biventricular pace-
aker placement within 60 days, expected survival of 6
onths, acute myocardial infarction at the time of hospi-
alization, hemodynamically significant uncorrected primary
ardiac valvular disease, end-stage HF, dialysis, systolic
lood pressure 90 mm Hg, serum creatinine more than t.5 mg/dl, serum potassium more
han 5.5 mEq/l, and hemoglobin
9 g/dl. Background therapy was
t the discretion of the treating
hysician, but specific recommen-
ations for guideline-based opti-
al medical therapy were included
n the study protocol. For admin-
strative reasons, B-type natriuretic
eptide (BNP) collection was in-
omplete, and we report on the
vailable samples from each center.
urthermore, the distribution of
NP measurements was highly
kewed, so we summarized BNP using the medians and
nterquartile ranges. For analysis of QRS duration, this
nterval was not reported in 142 patients, and 1,029 patients
ere excluded due to the presence of a pacemaker and/or
mplantable cardioverter-defibrillator (ICD).
In all, 4,133 patients were randomized in 359 sites in 20
ountries in the 3 continents of North America, South Amer-
ca, and Europe between October 7, 2003, and February 3,
006, with follow-up until July 6, 2006. For this analysis,
urope was divided into the regions of Eastern Europe and
estern Europe. The countries were grouped as follows:
orth America: U.S. and Canada; South America: Argentina
nd Brazil; Western Europe: Italy, Belgium, Norway,
etherlands, Germany, Spain, France, United Kingdom, Swe-
en, and Switzerland; and Eastern Europe: Poland, Romania,
zech Republic, Russia, Bulgaria, and Lithuania.
nd point assessment. The short-term primary end point
as a composite score of changes in patient-assessed global
linical status based on a visual analog scale and body weight
easured post-void on a standardized scale from baseline to
ay 7 or discharge if earlier. Long-term primary end points
ere all-cause mortality and the composite of CV death or
ospitalization for HF. The median follow-up period was
.9 months. The mode of death and CV hospitalizations
ere adjudicated by an independent event committee for all
atients during the follow-up period.
tatistical analysis. Post-hoc analyses were performed on
he entire randomized population, with patients grouped based
n continent of enrollment or region within Europe. Demo-
raphics, physical and laboratory findings, medical history, and
edical, revascularization, and device therapies were simulta-
eously compared among the 4 groups using the Kruskal-
allis test for continuous variables and the Pearson chi-square
est for categorical variables. Unadjusted Kaplan-Meier esti-
ates of the rates of all-cause mortality and CV death/HF
ospitalization were calculated at 3 months and 1 year. Hazard
atios (HRs) and corresponding confidence intervals (CIs) for
ortality and the composite end point were calculated relative
o North America at 3 months and over the entire follow-up
eriod (9.9 months median follow-up) using a Cox propor-
Abbreviations
and Acronyms
AHFS  acute heart failure
syndromes
BNP  B-type natriuretic
peptide
CI  confidence interval
CV  cardiovascular
HF  heart failure
HR  hazard ratio
ICD  implantable
cardioverter-defibrillatorional hazards model with and without adjustment for other
Bp
o
‡
i
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Table 1 Baseline Patient Characteristics
North America South America Western Europe Eastern Europe
Demographics
Number of patients (%) 1,251 (30.3) 699 (16.9) 564 (13.6) 1,619 (39.2)
Number of sites (%) 173 (48.2) 35 (9.7) 77 (21.4) 74 (20.6)
Number of patients per site 7.2 20.0 8.1 20.0
Number of countries (%) 2 (10.0) 2 (10.0) 10 (50.0) 6 (30.0)
Age, mean (SD), yrs 67.5 (12.8) 62.2 (12.4) 68.9 (11.3) 64.9 (10.5)
Men, n (%)* 935 (74.7) 521 (74.5) 446 (79.1) 1,173 (72.5)
Ethnicity, n (%)
White 943 (75.4) 419 (59.9) 555 (98.6) 1,616 (99.8)
Black 231 (18.5) 75 (10.7) 4 (0.7) 0 (0)
Other 77 (6.2) 205 (29.3) 4 (0.7) 3 (0.2)
Weight, mean (SD), kg 87.5 (20.9) 76.5 (17.6) 81.6 (17.5) 83.4 (17.3)
Physical and laboratory findings
Dyspnea, n (%) 1,077 (89.2) 605 (88.6) 450 (83.3) 1,547 (96.0)
Systolic BP, mean (SD), mm Hg 116.6 (19.2) 117.4 (18.6) 117.4 (19.8) 125.9 (19.2)
Diastolic BP, mean (SD), mm Hg 67.2 (13.0) 73.5 (12.2) 69.9 (11.2) 77.5 (11.1)
Heart rate, mean (SD), beats/min 78.1 (14.6) 79.7 (15.2) 78.5 (15.7) 81.7 (16.5)
NYHA functional class, n (%)
III 734 (58.7) 389 (41.3) 358 (63.5) 923 (57.0)
IV 463 (37.0) 295 (42.2) 175 (31.0) 689 (42.6)
JVD 10 cm, n (%) 365 (30.5) 261 (38.4) 79 (15.0) 377 (23.4)
Heart murmur, n (%) 711 (59.0) 386 (56.3) 237 (43.9) 1,012 (62.8)
Rales, n (%) 934 (77.3) 606 (88.3) 448 (82.8) 1,307 (81.1)
Pedal edema, n (%) 845 (70.0) 565 (82.4) 378 (69.9) 1,421 (88.2)
Ejection fraction, mean (SD), % 24.6 (8.5) 26.0 (7.4) 27.2 (7.6) 30.5 (7.1)
Serum BUN, mean (SD), mg/dl 35.1 (19.6) 28.3 (14.7) 35.1 (17.6) 25.7 (11.7)
Serum creatinine, mean (SD), mg/dl 1.5 (0.5) 1.4 (0.5) 1.5 (0.5) 1.2 (0.5)
Serum sodium, mean (SD), mg/dl 139.9 (4.4) 139.6 (5.3) 139.4 (4.6) 140.3 (4.5)
Arginine vasopressin, mean (SD), pg/ml 4.8 (3.7) 6.6 (6.2) 6.8 (7.7) 5.7 (5.3)
Serum BNP, median (IQR), pg/ml† 1,031 (470–2,100) 694 (296–1,405) 720 (366–1,467) 533 (222–1,225)
QRS 120 ms, n (%)‡ 267 (42.2) 331 (55.9) 187 (50.3) 536 (39.2)
Medical history, n (%)
Previous hospitalization for HF 1,002 (80.2) 503 (72.0) 431 (76.4) 1,314 (81.6)
CAD 968 (77.4) 279 (39.9) 361 (64.0) 1,303 (80.5)
Previous MI 694 (55.5) 206 (29.5) 275 (48.8) 912 (56.3)
Hypertension 984 (78.7) 486 (69.5) 305 (54.2) 1,157 (71.5)
Hypercholesterolemia 910 (72.8) 222 (31.8) 291 (51.7) 580 (35.8)
Mitral valve disease 628 (50.2) 121 (17.3) 209 (37.1) 346 (21.4)
Atrial fibrillation on admission 193 (15.5) 164 (23.5) 168 (30.1) 582 (36.0)
Diabetes 645 (51.6) 209 (29.9) 239 (42.4) 505 (31.2)
Chronic kidney disease 589 (47.1) 111 (15.9) 209 (37.1) 198 (12.2)
Severe COPD 226 (18.1) 40 (5.7) 62 (11.0) 88 (5.4)
Peripheral vascular disease 318 (25.4) 99 (14.2) 117 (20.7) 332 (20.5)
Revascularization and device use, n (%)
Previous PCI 407 (32.6) 86 (12.3) 138 (24.5) 107 (6.6)
Previous CABG 517 (41.4) 93 (13.3) 138 (24.5) 114 (7.0)
No ICD/pacemaker 655 (52.4) 605 (86.6) 404 (71.8) 1,438 (88.8)
Pacemaker 167 (13.4) 75 (10.7) 88 (15.6) 99 (6.1)
ICD 428 (34.2) 19 (2.7) 71 (12.6) 82 (5.1)
 0.001 for comparison between groups unless otherwise stated. Normal laboratory values: arginine vasopressin 0 to 8 pg/ml; B-type natriuretic peptide (BNP) 0 to 100 pg/ml. *p  0.020. †Number
f BNP samples varied across continents (see Methods section); n 709 (56.7%) for North America, 578 (82.7%) for South America, 405 (71.8%) for Western Europe, and 1,249 (77.2%) for Eastern Europe.
Number of QRS measurements (see Methods section); n  632 (50.5%) for North America, 592 (84.7%) for South America, 371 (66.0%) for Western Europe, and 1,366 (84.4%) for Eastern Europe.
BP  blood pressure; BUN  blood urea nitrogen; CABG  coronary artery bypass graft; CAD  coronary artery disease; COPD  chronic obstructive pulmonary disease; HF  heart failure; ICD 
mplantable cardioverter-defibrillator; IQR interquartile range; JVD jugular venous distention; MImyocardial infarction; NYHA New York Heart Association; PCI percutaneous coronary intervention.
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November 11, 2008:1640–8 Continental Differences in Acute HFaseline covariates. Baseline variables reaching a significance
evel of p  0.05 were retained.
The sponsor performed database management according to a
re-specified plan, and the University of Wisconsin Statistical
ata Analysis Center conducted all final analyses using SAS
oftware, version 8.2 (SAS Institute Inc., Cary, North Carolina)
nd R software (R Development Core Team, R Foundation
or Statistical Computing, Vienna, Austria). The authors had
ull access to the data and take responsibility for its integrity.
esults
f the 4,133 patients enrolled in 359 sites, there were 1,251
30.3%) patients, 173 (48.2%) sites, and 7.2 patients per site
n North America, 699 (16.9%) patients, 35 sites (9.7%),
nd 20.0 patients per site in South America, 564 (13.6%)
atients, 77 (21.4%) sites, and 8.1 patients per site in
Medications at Randomization and at Discharge
Table 2 Medications at Randomization and
North America So
At randomization n 1,249
ACE-I/ARBs 941 (75.2)
Beta-blocking agents 975 (78.1)
Spironolactone 408 (32.7)
Digoxin 548 (43.9)
Diuretics* 1,195 (95.7)
Lipid-lowering agents 743 (59.5)
Nitroglycerin 334 (26.7)
Amiodarone 235 (18.8)
Inotropic agents 95 (7.6)
IV nitroglycerin 44 (3.5)
Nesiritide 193 (15.5)
At discharge n 1,219
ACE-I/ARBs 943 (77.4)
Beta-blocking agents 997 (81.8)
Spironolactone 521 (42.7)
Digoxin 595 (48.8)
Diuretics 1,135 (93.1)
Lipid-lowering agents 724 (59.4)
Nitroglycerin 244 (20.0)
Amiodarone 261 (21.4)
Inotropic agents 50 (4.1)
IV nitroglycerin† 4 (0.3)
Nesiritide 85 (7.0)
p  0.001 for comparison between groups unless otherwise noted. *
ACE-I angiotensin-converting enzyme inhibitor; ARB angiotensi
nadjusted Kaplan-Meier Estimates of Outcomes
Table 3 Unadjusted Kaplan-Meier Estimates of Outcomes
North America South Am
3-month estimate, % (95% CI)
Death 11.4 (9.6–13.2) 11.3 (8.9–
CV death/HF hospitalization 29.8 (27.2–32.3) 21.3 (18.2
1-year estimate, % (95% CI)
Death 30.4 (27.6–33.1) 27.2 (23.3
CV death/HF hospitalization 52.5 (49.4–55.3) 41.6 (37.3I  confidence interval; CV  cardiovascular; HF  heart failure.estern Europe, and 1,619 (39.2%) patients, 74 (20.6%)
ites, and 20.0 patients per site in Eastern Europe.
There were several differences between continents and
egions (Table 1). The major differences are outlined in the
ollowing text.
hysical and laboratory findings. Patients in Eastern
urope had the highest systolic blood pressure (125.9
m Hg compared with 116.6, 117.4, and 117.4 mm Hg
n North America, South America, and Western Europe,
espectively) and left ventricular ejection fraction (30.5%
ompared with 24.6%, 26.0%, and 27.2% in North
merica, South America, and Western Europe, respec-
ively), and the lowest serum blood urea nitrogen (25.7
g/dl compared with 35.1, 28.3, and 35.1 mg/dl in
orth America, South America, and Western Europe,
espectively) and BNP (533 pg/ml compared with 1,031,
scharge
merica Western Europe Eastern Europe
99 n 563 n 1,619
3.1) 469 (83.2) 1,418 (87.6)
6.1) 362 (64.3) 1,174 (72.5)
4.4) 217 (38.5) 1,120 (69.2)
7.9) 196 (34.8) 834 (51.5)
7.1) 544 (96.6) 1,584 (97.8)
0.9) 261 (46.4) 379 (23.4)
.4) 128 (22.7) 188 (11.6)
0.0) 130 (23.1) 190 (11.7)
.4) 32 (5.7) 16 (1.0)
.2) 32 (5.7) 128 (7.9)
.0) 0 (0.0) 0 (0.0)
75 n 543 n 1,592
9.5) 470 (86.6) 1,400 (87.9)
2.8) 389 (71.6) 1,210 (76.0)
5.1) 259 (47.7) 1,068 (67.1)
5.7) 201 (37.0) 737 (46.3)
5.6) 531 (97.8) 1,441 (90.5)
2.1) 259 (47.7) 419 (26.3)
.3) 102 (18.8) 48 (3.0)
9.3) 124 (22.8) 188 (11.8)
.7) 6 (1.1) 5 (0.3)
.0) 1 (0.2) 0 (0.0)
.0) 0 (0.0) 0 (0.0)
1; †p 0.07.
tor blocker; IV intravenous.
Western Europe Eastern Europe p Value
12.1 (9.4–14.8) 6.8 (5.5–8.0) 0.0001
26.1 (22.3–29.6) 12.1 (10.5–13.7) 0.0001
27.1 (23.0–31.1) 20.5 (18.1–22.8) 0.0001
47.3 (42.6–51.7) 35.3 (32.4–38.0) 0.0001at Di
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nd Western Europe, respectively).
edical history. Patients in South America had the lowest
ates of coronary artery disease (39.9% compared with
7.4%, 64.0%, and 80.5% in North America, Western
urope, and Eastern Europe, respectively) and previous
yocardial infarction (29.5% compared with 55.5%, 48.8%,
nd 56.3% in North America, Western Europe, and Eastern
urope, respectively). Patients in Eastern Europe had the
ighest rate of atrial fibrillation on admission (36.0%
ompared with 15.5%, 23.5%, and 30.1% in North America,
outh America, and Western Europe, respectively), and
atients in North America had the highest rates of comor-
idities, including hypertension, hypercholesterolemia, dia-
Figure 1 Kaplan-Meier Analysis for
Cumulative Mortality by Region
EE  Eastern Europe; NA  North America;
SA  South America; WE  Western Europe.
Outcomes by Continent, Relative to North Amer
Table 4 Outcomes by Continent, Relative to
South Ame
Unadjusted analysis, HR (95% CI)
Death
3 months 1.00 (0.76–1
Overall 0.91 (0.76–1
CV death/HF hospitalization
3 months 0.68 (0.56–0
Overall 0.74 (0.65–0
Adjusted analysis, HR (95% CI)*
Death
3 months 1.58 (1.11–2
Overall 1.42 (1.15–1
CV death/HF hospitalization
3 months 1.08 (0.86–1
Overall 1.11 (0.94–1
*Adjusted for age, race, etiology, history of myocardial infarction, histo
renal insufficiency, atrial arrhythmia, systolic blood pressure, murm
peptide, sodium, angiotensin-converting enzyme/angiotensin receptor blocke
HR  hazard ratio; other abbreviations as in Table 3.etes, chronic kidney disease, severe obstructive lung dis-
ase, and peripheral vascular disease.
evascularization and device use. The use of percutane-
us and surgical revascularization was highest in North
merica (32.6% and 41.4%) and Western Europe (24.5%
nd 24.5%) and lowest in South America (12.3% and
3.3%) and Eastern Europe (6.6% and 7.0%). A similar
attern was found for pacemaker use. The use of ICDs was
he highest in North America (34.2% compared with 2.7%,
2.6%, and 5.1% in South America, Western Europe, and
astern Europe, respectively).
edication use. Most patients were on diuretic therapy at
andomization and at discharge (Table 2). There was
reater beta-blocker use in North America and Eastern
urope, greater use of nitroglycerin and lipid-lowering
gents in North America and Western Europe, greater use
f spironolactone in South America and Eastern Europe,
nd equal use of digoxin across all regions except for
estern Europe. Inotropic agent use was highest in North
merica (7.6% at randomization compared with 3.4%,
.7%, and 1.0% in South America, Western Europe, and
astern Europe, respectively). Most patients were off ino-
ropic agents and intravenous nitroglycerin by discharge,
xcept for a small percentage of patients (4.1%) in North
merica still on inotropic agents. As seen in Table 2, the
ddition of medications known to improve long-term out-
omes in patients with HF such as angiotensin-converting
nzyme inhibitors/angiotensin receptor blockers, beta-
lockers, and spironolactone occurred infrequently during
ospitalization and did not substantially differ across
egions.
utcomes. Unadjusted 1-year Kaplan-Meier estimates of
ortality were highest in North America (30.4%), followed
y South America (27.2%), Western Europe (27.1%), and
astern Europe (20.5%) (Table 3, Fig. 1). Compared with
h America
Western Europe Eastern Europe
1.06 (0.80–1.42) 0.57 (0.44–0.73)
0.97 (0.81–1.16) 0.63 (0.54–0.73)
0.86 (0.71–1.04) 0.36 (0.30–0.42)
0.89 (0.78–1.03) 0.52 (0.47–0.59)
1.31 (0.94–1.82) 1.10 (0.80–1.51)
1.16 (0.95–1.42) 1.17 (0.98–1.41)
1.18 (0.95–1.46) 0.65 (0.52–0.80)
1.10 (0.93–1.28) 0.84 (0.73–0.97)
hospitalization, New York Heart Association functional class, chronic
ventricular ejection fraction, blood urea nitrogen, B-type natriureticica
Nort
rica
.32)
.08)
.82)
.86)
.25)
.76)
.37)
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November 11, 2008:1640–8 Continental Differences in Acute HForth America, the overall unadjusted risk of death was
imilar in South America and Western Europe, but was
ignificantly lower in Eastern Europe (HR: 0.63, 95% CI:
.54 to 0.73) (Table 4). After adjusting for important
aseline characteristics, the overall risk of death was similar
n Western Europe and Eastern Europe, but elevated in
atients from South America (HR: 1.58, 95% CI: 1.11 to
.25 at 3 months; HR: 1.42, 95% CI: 1.15 to 1.76 overall)
ompared with that in North America.
Unadjusted 1-year Kaplan-Meier estimates of CV death
r HF hospitalization were highest in North America
52.5%), followed by Western Europe (47.3%), South
merica (41.6%), and Eastern Europe (35.3%) (Table 3,
Figure 2 Kaplan-Meier Analysis for Cardiovascular
Mortality or HF Hospitalization by Region
HF  heart failure; other abbreviations as in Figure 1.
verall Event Rates
Table 5 Overall Event Rates
North America
Mortality, n (%) n 434
HF 186 (42.9)
Acute MI 7 (1.6)
SCD 90 (20.7)
Stroke 9 (2.1)
Other CV mortality 18 (4.1)
Noncardiovascular 72 (16.6)
Unknown 52 (12.0)
Rehospitalization events, n (%) n 932
HF 529 (56.8)
MI 29 (3.1)
Arrhythmia 105 (11.3)
Stroke 22 (2.4)
Other CV hospitalization 131 (14.1)
Unscheduled visit for HF 116 (12.4)
Early treatment termination, % (95% CI)
Kaplan-Meier estimates, 1 yr 33.7 (30.7–36.6)CD  sudden cardiac death; other abbreviations as in Tables 1 and 3.ig. 2). Compared with North America, the overall unad-
usted risk for CV death or HF hospitalization was similar
n Western Europe, but lower in South America and
astern Europe. After adjusting for baseline variables,
astern Europe was the only region with lower overall CV
eath or HF hospitalization rates (HR: 0.84, 95% CI: 0.73
o 0.97) compared with North America (Table 4).
After adjudication of all events in the study, the main
ause of death was HF in North America, South America,
nd Western Europe (42.9%, 44.0%, and 47.9%, respec-
ively), whereas it was sudden cardiac death in Eastern
urope (35.5%) (Table 5). The main reason for rehospital-
zation was HF in all continents.
Early treatment termination at 1 year was most common
n North America (33.7%), followed by Western Europe
24.3%), Eastern Europe (14.2%), and South America
13.5%), and did not differ based on active medication.
The 2 components of the short-term primary end point
ere weight loss and change in baseline global status
rom randomization to day 7 or discharge if sooner. It
ppeared that there was a significant difference between
ontinents and regions in weight loss (p  0.022), but
ot in global status (Figs. 3 and 4) when comparing the
olvaptan groups to placebo groups. In terms of the
ong-term primary end points, the addition of tolvaptan
o standard therapy did not appear to affect post-
ischarge or the combined end point of CV mortality and
F hospitalization in any of the 4 regions (15).
iscussion
his study demonstrates significant differences in HF se-
erity, etiology, and management among different conti-
ents and regions in a large, international trial in AHFS.
h America Western Europe Eastern Europe
 184 n 163 n 299
(44.0) 78 (47.9) 98 (32.8)
(0.0) 2 (1.2) 19 (6.4)
(27.7) 34 (20.9) 106 (35.5)
(2.7) 3 (1.8) 7 (2.3)
(4.9) 8 (4.9) 19 (6.4)
(15.2) 29 (17.8) 14 (4.7)
(5.4) 9 (5.5) 36 (12.0)
 326 n 309 n 555
(65.0) 197 (63.8) 348 (62.7)
(0.9) 6 (1.9) 29 (5.2)
(6.4) 21 (6.8) 44 (7.9)
(4.3) 7 (2.3) 26 (4.7)
(16.3) 63 (20.4) 95 (17.1)
(7.1) 15 (4.9) 13 (2.3)
(10.5–16.4) 24.3 (20.2–28.2) 14.2 (12.1–16.2)Sout
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Continental Differences in Acute HF November 11, 2008:1640–8ifferences in HF severity. Several variables have been
dentified that are important predictors of prognosis in
HFS and in chronic HF. Of the variables measured in the
VEREST program, low systolic blood pressure and serum
odium, and high BNP, blood urea nitrogen, and creatinine
re independent predictors of adverse outcomes in AHFS
nd chronic HF (9,17–23). The Eastern European popula-
ion had the highest systolic blood pressure and ejection
raction and the lowest blood urea nitrogen and BNP
ompared with the populations of other regions, placing
hem at lower risk for death and HF hospitalization.
ifferences in HF etiology. Patients from South America
ad the lowest rates of coronary artery disease, previous
yocardial infarction, and hypercholesterolemia. Other co-
orbidities, such as diabetes and peripheral vascular disease,
ere the lowest in South America compared with other
ontinents and regions. The low rates of coronary artery
isease as well as other comorbidities were similar in registry
ata obtained from Argentina (12). In addition, patients in
hese registries had high rates of hypertensive and valvular
F (23.7% and 20.7%), with a noticeable but low rate of
Figure 3 Weight Loss on Day 7 or Discharge
Group A  tolvaptan; group B  placebo.
Figure 4 Global Clinical Status on a Visual Analog Scale on Da
Group A  tolvaptan; group B  placebo.hagas HF (1.3%), suggesting that the underlying disease
rocess in South America is different than in other continents.
ifferences in HF management. Despite similarities in
F guidelines in the U.S. and Europe, there were impor-
ant differences in medications, revascularization proce-
ures, and device use between continents and regions
24,25). For example, use of lipid-lowering agents was most
requent in North America and Western Europe, whereas
se of spironolactone was most frequent in South America
nd Eastern Europe. Diuretic and digoxin use was numer-
cally similar across continents and regions. The reasons for
his variation have been analyzed in prior studies and may
epend on multiple factors ranging from patient character-
stics to the reimbursement structure of the particular
ountry (26,27). There was also a difference in beta-blocker
se, with a 22% lower rate of use in South America than in
orth America. Revascularization, pacemaker, and ICD use
as highest in North America and Western Europe and
owest in South America and Eastern Europe.
ifferences in outcomes. The differences in HF severity,
tiology, and treatment were associated with differences in
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November 11, 2008:1640–8 Continental Differences in Acute HFutcome in the EVEREST trial. The Eastern European
opulation, for example, had the best overall unadjusted
hort- and long-term outcomes compared with the other
ontinents or regions, likely due to the low severity of HF at
andomization in this trial. After adjustment for major
ovariates, this difference in outcomes disappeared, stressing
he importance of these variables on outcome.
mplications. This analysis has implications in the design
f future AHFS trials. The main inclusion criterion for
HFS trials is based on the perceived need for hospital
dmission. Since this may be influenced by differences in
ocal medical practice as well as by differences in health care
ystems, using objective measurements of severity (e.g.,
NP levels) may help enroll a more homogenous group of
atients. In addition, a drug effect may be observed in
elation to the etiology predominant to a particular region.
or example, in the OPTIME-CHF (Outcomes of a
rospective Trial of Intravenous Milrinone for Exacerbation
f Chronic Heart Failure) study, the short-term use of
ilrinone was deleterious and was associated with a signif-
cant increase in post-discharge mortality only in patients
ith coronary artery disease (28). Finally, the effects of a
articular investigational drug may be affected by back-
round HF therapies. For example, it is possible that
nterventions targeted to sudden cardiac death or progres-
ion of HF may not improve outcomes in patients already
reated with ICDs or cardiac resynchronization therapy, the
se of which varied dramatically between continents and
egions.
tudy limitations. Our analysis was performed on data
igorously collected in the setting of a clinical trial, with
very patient chosen based on pre-specified strict selec-
ion criteria, and may not represent the true severity,
tiology, and management in a given region. Registries of
onsecutive patients may better identify differences be-
ween regions. Nevertheless, knowing differences be-
ween regions in a large clinical trial is important for trial
esign. In addition, this was a subgroup analysis. Al-
hough adjusted analysis has been performed considering
he possible confounding factors, differences could be due
o chance, and potential confounders may not have been
dentified.
onclusions
hese data demonstrated that despite efforts to select for
fairly homogenous study population, important differ-
nces in etiology, severity, management, and outcomes
xisted. The etiology and management of HF may vary by
egion and is difficult to control. Future AHFS trials
hould take these continental and regional differences
nto consideration and possibly stratify randomization
ased on continent or region when appropriate and
nalyze the data separately.eprint requests and correspondence: Dr. Mihai Gheorghiade,
orthwestern University, Feinberg School of Medicine, 201 East
uron Street, Galter 10-240, Chicago, Illinois 60611. E-mail:
-gheorghiade@northwestern.edu.
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